NCT04102930 Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
| NCT ID | NCT04102930 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Leeds |
| Condition | Giant Cell Arteritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,500 participants |
| Start Date | 2005-06-10 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,500 participants in total. It began in 2005-06-10 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A multi-centre observational study recruiting prospective and retrospective cohorts of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). The primary aim is to find genetic determinants of GCA and PMR susceptibility, in order to yield novel insights into disease pathogenesis. A subset of the retrospective cohort is also enrolled in a post-marketing surveillance registry of patients eligible for, or receiving tocilizumab, to treat their relapsing or refractory GCA.
Eligibility Criteria
Inclusion Criteria: * Willing to self-identify an ethnic group, such as Caucasian, Asian, Afro-Caribbean. * Have a firm clinical diagnosis of GCA or PMR, or (for patients identified prospectively) GCA or PMR should be more likely than any alternative explanation for the patient's symptoms. * Able and willing to give informed consent. Patients will be 50 years of age or over, unless both biopsy-proven and a clinically classical case of GCA. Exclusion Criteria: • Patient unwilling or unable to give fully informed consent.
Contact & Investigator
Ann Morgan
PRINCIPAL INVESTIGATOR
University of Leeds
Frequently Asked Questions
Who can join the NCT04102930 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Giant Cell Arteritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04102930 currently recruiting?
Yes, NCT04102930 is actively recruiting participants. Contact the research team at MRCTarget@leeds.ac.uk for enrollment information.
Where is the NCT04102930 trial being conducted?
This trial is being conducted at Canterbury, United Kingdom, Prescot, United Kingdom, Abergavenny, United Kingdom, Aylesbury, United Kingdom and 11 additional locations.
Who is sponsoring the NCT04102930 clinical trial?
NCT04102930 is sponsored by University of Leeds. The principal investigator is Ann Morgan at University of Leeds. The trial plans to enroll 4,500 participants.